Recent Finacing
Recent Raise
Prilenia Therapeutics is a clinical‑stage biotechnology company developing pridopidine, an oral selective sigma‑1 receptor agonist in Phase 3 PROOF‑HD for Huntington’s disease and in the HEALEY ALS platform trial.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Prilenia.
